Immunotherapy in Melanoma | Specialty

Expert Anticipates Exciting Advances in Adjuvant Melanoma

March 21st 2017

Jason J. Luke, MD, discusses adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy.

Melanoma Knowledge Starts With Dermatologists, Expert Says

March 21st 2017

Christopher R. Shea, MD, expresses the importance of expanding melanoma knowledge to more specialists as well as the advancements in pathology over the last several years.

Dr. Luke on Adjuvant Therapies in Development for Melanoma

March 20th 2017

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.

Binimetinib Application for NRAS-Mutant Melanoma Withdrawn

March 20th 2017

Array BioPharma has withdrawn its new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma, based on feedback from the FDA during a preplanned review meeting.

Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial

March 20th 2017

Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.

Vaccine Shows Promise in Renal Cell Carcinoma

March 3rd 2017

Hans J. Hammers, MD, PhD, discusses early promising data for HyperAcute Renal immunotherapy in renal cell carcinoma and the overall potential for vaccines in the field.

Combos Mark Next Step in Melanoma Immunotherapy

February 27th 2017

Evidence continues to build for the long-term efficacy of PD-1-targeting immunotherapies in melanoma, including fresh data indicating when patients can stop taking the drugs and still maintain a response.

Focus on Cancer Prevention Would Moderate Spiraling Costs of Care

February 24th 2017

Certain components of the cancer care continuum have the potential to favorably impact the rapidly encroaching crisis in cancer care costs at the societal level.

Dr. Freeman on Challenges in Treatment Selection in Melanoma

February 14th 2017

Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

Dr. Weber on Combination Strategies for BRAF-Mutant Melanoma

February 14th 2017

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for patients with BRAF-mutant melanoma.

Dr. Gangadhar on Combination Regimens for Melanoma

February 14th 2017

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.

Dr. Postow on Immunotherapy Advancements in Melanoma

February 13th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the advancements that have recently taken place in immunotherapy in the field of melanoma.

Dr. Hamid on Melanoma as a Therapeutic Driver for Other Cancers

February 12th 2017

Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses melanoma as a therapeutic driver for other tumor types during the 13th Annual 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® in Sunny Isles Beach, Florida.

Less Common Side Effects With Immunotherapy in Melanoma

February 8th 2017

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

February 8th 2017

Melanoma: Testing for Immunotherapy-Related Hepatotoxicity

February 8th 2017

Immunotherapy-Related Pulmonary Toxicities in Melanoma

February 8th 2017

Managing Gastrointestinal Toxicities in Melanoma

February 8th 2017

Melanoma: Management of Dermatologic Toxicities

February 8th 2017

Overall Toxicities With Immunotherapy in Melanoma

February 8th 2017